PMID- 34425689
OWN - NLM
STAT- MEDLINE
DCOM- 20220428
LR  - 20220525
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 56
IP  - 5
DP  - 2022 May
TI  - Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: An Updated 
      Meta-analysis.
PG  - 524-532
LID - 10.1177/10600280211039240 [doi]
AB  - BACKGROUND: Some studies suggested an increased risk of community-acquired 
      pneumonia (CAP) among proton pump inhibitors (PPI) users. However, the published 
      evidence is inadequate to define the association between PPI use and the risk of 
      CAP. OBJECTIVE: The aims of our meta-analysis were to systematically assess the 
      association between the risk of CAP and PPI use in adults to reduce the adverse 
      effects of PPI and ensure the safety of medication for patients. METHODS: A 
      comprehensive literature search was conducted, published between January 1, 2004, 
      and February 1, 2021. The primary outcome was the incidence of CAP. This 
      meta-analysis was performed using odds ratios (ORs) with 95% CIs as effective 
      measures; 13 studies including 2 098 804 patients were enrolled in our 
      meta-analysis. RESULTS: Our study revealed that the incidence of CAP was higher 
      in PPI users than non -PPI users [OR = 1.37 (95% CI = 1.22-1.53)], especially for 
      PPI duration < 30 days [OR = 1.49 (95% CI = 1.34-1.66)]. Compared with non-PPI 
      use, PPI use increased the incidence of CAP in the stroke disease population [OR 
      = 1.52 (95% CI = 1.33-1.75)], but not in the liver disease population [OR = 1.13 
      (95% CI = 0.98-1.30)]. CONCLUSIONS AND RELEVANCE: Using PPI could increase the 
      risk of CAP when compared to not using PPI. PPI use increased the incidence of 
      CAP in patients with stroke. Clinicians and clinical pharmacists should weigh the 
      benefits before medication and strictly control the indication of the 
      prescription, so as to reduce adverse reactions.
FAU - Xun, Xuejiao
AU  - Xun X
AD  - Hebei General Hospital, Shijiazhuang, Hebei Province, China.
FAU - Yin, Qifan
AU  - Yin Q
AD  - Hebei General Hospital, Shijiazhuang, Hebei Province, China.
AD  - Hebei Medical University First Affiliated Hospital, Shijiazhuang, Hebei Province, 
      China.
FAU - Fu, Yuhao
AU  - Fu Y
AD  - Hebei General Hospital, Shijiazhuang, Hebei Province, China.
FAU - He, Xueru
AU  - He X
AD  - Hebei General Hospital, Shijiazhuang, Hebei Province, China.
FAU - Dong, Zhanjun
AU  - Dong Z
AUID- ORCID: 0000-0002-9331-621X
AD  - Hebei General Hospital, Shijiazhuang, Hebei Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210823
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - *Community-Acquired Infections/drug therapy/epidemiology
MH  - Humans
MH  - Odds Ratio
MH  - *Pneumonia/chemically induced/drug therapy/epidemiology
MH  - Proton Pump Inhibitors/adverse effects
MH  - Risk Factors
MH  - *Stroke/drug therapy
OTO - NOTNLM
OT  - association
OT  - community-acquired pneumonia
OT  - meta-analysis
OT  - proton pump inhibitors
OT  - stroke
EDAT- 2021/08/25 06:00
MHDA- 2022/04/29 06:00
CRDT- 2021/08/24 05:25
PHST- 2021/08/25 06:00 [pubmed]
PHST- 2022/04/29 06:00 [medline]
PHST- 2021/08/24 05:25 [entrez]
AID - 10.1177/10600280211039240 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2022 May;56(5):524-532. doi: 10.1177/10600280211039240. Epub 
      2021 Aug 23.